Areeba Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Areeba Khan has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Sandipkumar S. Chaudhari
Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, USA
8 shared publicationsAnurag Rawat
Interventional Cardiology, Himalayan Institute of Medical Sciences, Dehradun, IND
5 shared publications- Calvin Ronchen Wei
Department of Research and Development Shing Huei Group Taipei Taiwan
4 shared publications - Rahat Ahmed Memon
Abington Hosp- Jefferson Health, Horsham, PA
3 shared publications - Faraz Saleem
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
2 shared publications - Hayan Kundi
Medicine, Fazaia Medical College, Karachi, PAK
2 shared publications
Latest Publications
- Open Access
- 20 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10)
Dapagliflozin and Anemia Outcomes: A Systematic Review and Meta-Analysis of Effects on Hemoglobin Levels, Anemia Correction, and Incidence in Patients With and Without Heart Failure
This systematic review and meta-analysis evaluated the impact of dapagliflozin on anemia outcomes across different patient populations. A comprehensive literature search was conducted across multiple databases from inception to September 2025, identifying studies that reported anemia-related outcomes in adult patients receiving dapagliflozin treatment. Seven studies comprising 15,540 participants were included, encompassing randomized controlled trials and observational studies conducted across diverse geographical regions. All studies evaluated 10 mg of dapagliflozin once daily with a minimum four-week follow-up duration. The pooled analysis demonstrated significant improvements in hemoglobin levels with dapagliflozin compared to control groups (standardized mean difference [SMD]: 0.62; 95% CI: 0.43-0.80). Dapagliflozin treatment was associated with an 83% higher likelihood of anemia correction (relative risk: 1.83; 95% CI: 1.47-2.26) and a 78% reduction in anemia incidence (relative risk: 0.22; 95% CI: 0.08-0.60). Subgroup analyses revealed consistent benefits across all studied populations, with the most pronounced effects observed in heart failure patients (SMD: 0.78; 95% CI: 0.44-1.12), followed by chronic kidney disease (0.66; 95% CI: 0.36-0.95) and diabetes patients (0.45; 95% CI: 0.38-0.51). These findings suggest that dapagliflozin's therapeutic benefits extend beyond cardiovascular and renal protection to include meaningful improvements in anemia outcomes across multiple chronic disease states, potentially reducing healthcare burden and improving patient quality of life.
- 20 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10)
Open AccessDapagliflozin and Anemia Outcomes: A Systematic Review and Meta-Analysis of Effects on Hemoglobin Levels, Anemia Correction, and Incidence in Patients With and Without Heart Failure
This systematic review and meta-analysis evaluated the impact of dapagliflozin on anemia outcomes across different patient populations. A comprehensive literature search was conducted across multiple databases from inception to September 2025, identifying studies that reported anemia-related outcomes in adult patients receiving dapagliflozin treatment. Seven studies comprising 15,540 participants were included, encompassing randomized controlled trials and observational studies conducted across diverse geographical regions. All studies evaluated 10 mg of dapagliflozin once daily with a minimum four-week follow-up duration. The pooled analysis demonstrated significant improvements in hemoglobin levels with dapagliflozin compared to control groups (standardized mean difference [SMD]: 0.62; 95% CI: 0.43-0.80). Dapagliflozin treatment was associated with an 83% higher likelihood of anemia correction (relative risk: 1.83; 95% CI: 1.47-2.26) and a 78% reduction in anemia incidence (relative risk: 0.22; 95% CI: 0.08-0.60). Subgroup analyses revealed consistent benefits across all studied populations, with the most pronounced effects observed in heart failure patients (SMD: 0.78; 95% CI: 0.44-1.12), followed by chronic kidney disease (0.66; 95% CI: 0.36-0.95) and diabetes patients (0.45; 95% CI: 0.38-0.51). These findings suggest that dapagliflozin's therapeutic benefits extend beyond cardiovascular and renal protection to include meaningful improvements in anemia outcomes across multiple chronic disease states, potentially reducing healthcare burden and improving patient quality of life.
- Open Access
- 5 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9)
Efficacy and Safety of Lorundrostat in Patients With Uncontrolled and Treatment-Resistant Hypertension: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis evaluated the efficacy and safety of lorundrostat, a novel aldosterone synthase inhibitor, in patients with uncontrolled or treatment-resistant hypertension. A comprehensive literature search was conducted across major electronic databases, including MEDLINE, Embase, Cochrane CENTRAL, Web of Science, and Scopus through July 25, 2025. Randomized controlled trials comparing lorundrostat to placebo in adult patients with uncontrolled hypertension were included. Three studies met the inclusion criteria and were analyzed using Review Manager 5.4.1 (The Cochrane Collaboration, London, England, UK) with random-effects models. The pooled analysis demonstrated that lorundrostat achieved a statistically significant reduction in systolic blood pressure of 8.04 mmHg compared to placebo (95% confidence interval (CI): -10.69 to -5.39) with low heterogeneity (I2 = 28%). Subgroup analysis revealed comparable efficacy between 50 mg and 100 mg doses, suggesting a relatively flat dose-response relationship within this range. This magnitude of blood pressure reduction is clinically meaningful and comparable to established fourth-line therapies like spironolactone. Regarding safety, lorundrostat was associated with a significantly higher risk of adverse events compared to placebo (risk ratio (RR): 1.47; 95% CI: 1.32 to 1.64), though most were mild to moderate in severity. Importantly, no significant difference was observed in serious adverse events (RR: 1.01; 95% CI: 0.39 to 2.63), providing reassurance about the overall safety profile. These findings suggest that lorundrostat represents a promising therapeutic option for treatment-resistant hypertension, offering clinically significant blood pressure reductions with an acceptable safety profile. However, long-term cardiovascular outcome studies and direct comparisons with existing therapies are needed to fully establish its clinical role.
- 5 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9)
Open AccessEfficacy and Safety of Lorundrostat in Patients With Uncontrolled and Treatment-Resistant Hypertension: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis evaluated the efficacy and safety of lorundrostat, a novel aldosterone synthase inhibitor, in patients with uncontrolled or treatment-resistant hypertension. A comprehensive literature search was conducted across major electronic databases, including MEDLINE, Embase, Cochrane CENTRAL, Web of Science, and Scopus through July 25, 2025. Randomized controlled trials comparing lorundrostat to placebo in adult patients with uncontrolled hypertension were included. Three studies met the inclusion criteria and were analyzed using Review Manager 5.4.1 (The Cochrane Collaboration, London, England, UK) with random-effects models. The pooled analysis demonstrated that lorundrostat achieved a statistically significant reduction in systolic blood pressure of 8.04 mmHg compared to placebo (95% confidence interval (CI): -10.69 to -5.39) with low heterogeneity (I2 = 28%). Subgroup analysis revealed comparable efficacy between 50 mg and 100 mg doses, suggesting a relatively flat dose-response relationship within this range. This magnitude of blood pressure reduction is clinically meaningful and comparable to established fourth-line therapies like spironolactone. Regarding safety, lorundrostat was associated with a significantly higher risk of adverse events compared to placebo (risk ratio (RR): 1.47; 95% CI: 1.32 to 1.64), though most were mild to moderate in severity. Importantly, no significant difference was observed in serious adverse events (RR: 1.01; 95% CI: 0.39 to 2.63), providing reassurance about the overall safety profile. These findings suggest that lorundrostat represents a promising therapeutic option for treatment-resistant hypertension, offering clinically significant blood pressure reductions with an acceptable safety profile. However, long-term cardiovascular outcome studies and direct comparisons with existing therapies are needed to fully establish its clinical role.
- Open Access
- 17 July 2025
- Published by Springer Nature in Cureus
- Vol. 17 (7) , e88134
Clinical Outcomes in Blood Culture-Positive Versus Blood Culture-Negative Infective Endocarditis: A Systematic Review and Meta-Analysis
Infective endocarditis (IE) cases where blood cultures fail to identify causative organisms, known as blood culture-negative endocarditis (BCNE), represent a significant portion of all endocarditis diagnoses. This absence of microbiological identification creates therapeutic challenges, as clinicians cannot tailor antimicrobial therapy to specific pathogens. The relationship between microbiological culture results and patient prognosis continues to be an area requiring further investigation. This systematic review and meta-analysis compared clinical outcomes between blood culture-positive endocarditis (BCPE) and BCNE patients. We conducted a comprehensive search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library from inception to May 2025. Observational studies comparing outcomes between BCPE and BCNE in adult patients were included. Primary outcomes were mortality, embolic events, and need for surgery. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Seven studies encompassing 5,349 participants were included, with a pooled BCNE prevalence of 16.8%. No significant difference was found in mortality between BCPE and BCNE groups (RR: 0.98, 95% CI: 0.76-1.25). However, BCPE patients had a significantly higher risk of embolic events compared to BCNE patients (RR: 1.38, 95% CI: 1.16-1.63). No significant difference was observed in surgical intervention rates (RR: 0.98, 95% CI: 0.75-1.27). Secondary analysis revealed that BCPE patients had higher rates of fever and abscess formation but a lower incidence of heart failure compared to BCNE patients. While mortality and surgical outcomes were similar between groups, blood culture-positive IE patients demonstrated significantly higher embolic complications. These findings suggest that culture-positive status may serve as a marker for increased embolic risk, warranting enhanced monitoring and early intervention strategies in clinical practice.
- 17 July 2025
- Published by Springer Nature in Cureus
- Vol. 17 (7) , e88134
Open AccessClinical Outcomes in Blood Culture-Positive Versus Blood Culture-Negative Infective Endocarditis: A Systematic Review and Meta-Analysis
Infective endocarditis (IE) cases where blood cultures fail to identify causative organisms, known as blood culture-negative endocarditis (BCNE), represent a significant portion of all endocarditis diagnoses. This absence of microbiological identification creates therapeutic challenges, as clinicians cannot tailor antimicrobial therapy to specific pathogens. The relationship between microbiological culture results and patient prognosis continues to be an area requiring further investigation. This systematic review and meta-analysis compared clinical outcomes between blood culture-positive endocarditis (BCPE) and BCNE patients. We conducted a comprehensive search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library from inception to May 2025. Observational studies comparing outcomes between BCPE and BCNE in adult patients were included. Primary outcomes were mortality, embolic events, and need for surgery. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Seven studies encompassing 5,349 participants were included, with a pooled BCNE prevalence of 16.8%. No significant difference was found in mortality between BCPE and BCNE groups (RR: 0.98, 95% CI: 0.76-1.25). However, BCPE patients had a significantly higher risk of embolic events compared to BCNE patients (RR: 1.38, 95% CI: 1.16-1.63). No significant difference was observed in surgical intervention rates (RR: 0.98, 95% CI: 0.75-1.27). Secondary analysis revealed that BCPE patients had higher rates of fever and abscess formation but a lower incidence of heart failure compared to BCNE patients. While mortality and surgical outcomes were similar between groups, blood culture-positive IE patients demonstrated significantly higher embolic complications. These findings suggest that culture-positive status may serve as a marker for increased embolic risk, warranting enhanced monitoring and early intervention strategies in clinical practice.
- Open Access
- 13 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4)
Lactate-to-Albumin Ratio (LAR) as a Predictor of All-Cause Mortality in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis
Myocardial infarction (MI) remains a significant global health challenge, necessitating innovative approaches for early risk stratification. This systematic review and meta-analysis investigated the prognostic value of the lactate-to-albumin ratio (LAR) in predicting all-cause mortality among MI patients. A comprehensive literature search was conducted across PubMed, Embase, Web of Science, and Google Scholar, encompassing studies published until March 10, 2025. The meta-analysis included five studies involving 8,408 subjects with MI, all conducted in China between 2022 and 2024. Studies were selected based on predefined eligibility criteria, focusing on observational cohort and case-control designs, with LAR measured at admission and mortality outcomes reported. Pooled analysis revealed that patients with high LAR experienced approximately twice the risk of all-cause mortality compared to those with low LAR (hazard ratio: 2.08, 95% confidence interval: 1.70-2.54, p < 0.001). Significant heterogeneity was observed among studies (I2: 75%), which may be attributed to variations in patient populations and measurement methodologies. Despite limitations such as retrospective study designs and potential selection bias, the findings suggest LAR as a promising, accessible biomarker for early risk stratification in MI patients. Future research should focus on prospective studies to validate these results, establish standardized measurement protocols, and explore the underlying physiological mechanisms linking LAR to adverse outcomes.
- 13 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4)
Open AccessLactate-to-Albumin Ratio (LAR) as a Predictor of All-Cause Mortality in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis
Myocardial infarction (MI) remains a significant global health challenge, necessitating innovative approaches for early risk stratification. This systematic review and meta-analysis investigated the prognostic value of the lactate-to-albumin ratio (LAR) in predicting all-cause mortality among MI patients. A comprehensive literature search was conducted across PubMed, Embase, Web of Science, and Google Scholar, encompassing studies published until March 10, 2025. The meta-analysis included five studies involving 8,408 subjects with MI, all conducted in China between 2022 and 2024. Studies were selected based on predefined eligibility criteria, focusing on observational cohort and case-control designs, with LAR measured at admission and mortality outcomes reported. Pooled analysis revealed that patients with high LAR experienced approximately twice the risk of all-cause mortality compared to those with low LAR (hazard ratio: 2.08, 95% confidence interval: 1.70-2.54, p < 0.001). Significant heterogeneity was observed among studies (I2: 75%), which may be attributed to variations in patient populations and measurement methodologies. Despite limitations such as retrospective study designs and potential selection bias, the findings suggest LAR as a promising, accessible biomarker for early risk stratification in MI patients. Future research should focus on prospective studies to validate these results, establish standardized measurement protocols, and explore the underlying physiological mechanisms linking LAR to adverse outcomes.
- Open Access
- 15 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e80609
Efficacy of Tislelizumab in Lung Cancer Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
This systematic review and meta-analysis evaluated the efficacy of tislelizumab, alone or in combination with chemotherapy, in patients with lung cancer. A comprehensive literature search was conducted across PubMed, Embase, Web of Science, and CENTRAL databases until February 15, 2025. Only randomized controlled trials (RCTs) comparing tislelizumab with control treatments in lung cancer patients were included. The primary outcomes assessed were overall survival (OS) and progression-free survival (PFS). Four phase-III RCTs involving 1,837 patients were included in the analysis. The results demonstrated that tislelizumab significantly improved OS (hazard ratios (HR): 0.72, 95% CI: 0.63-0.81) and PFS (HR: 0.61, 95% CI: 0.54-0.68) compared to control treatments. Subgroup analyses revealed consistent benefits across both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) populations, with no significant differences between cancer types. Similarly, the efficacy of tislelizumab was comparable whether administered as monotherapy or in combination with chemotherapy. Low heterogeneity was observed among the included studies, suggesting consistency in treatment effects. Follow-up duration across studies ranged from 14.2 to 16.7 months. These findings indicate that tislelizumab, either alone or combined with chemotherapy, is an effective treatment option for lung cancer patients, demonstrating significant improvements in survival outcomes. However, further high-quality RCTs are needed to validate these results, particularly in SCLC patients, where evidence is limited to a single study. Future research should also consider patient-specific factors such as age, gender, and comorbidities to refine treatment strategies.
- 15 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e80609
Open AccessEfficacy of Tislelizumab in Lung Cancer Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
This systematic review and meta-analysis evaluated the efficacy of tislelizumab, alone or in combination with chemotherapy, in patients with lung cancer. A comprehensive literature search was conducted across PubMed, Embase, Web of Science, and CENTRAL databases until February 15, 2025. Only randomized controlled trials (RCTs) comparing tislelizumab with control treatments in lung cancer patients were included. The primary outcomes assessed were overall survival (OS) and progression-free survival (PFS). Four phase-III RCTs involving 1,837 patients were included in the analysis. The results demonstrated that tislelizumab significantly improved OS (hazard ratios (HR): 0.72, 95% CI: 0.63-0.81) and PFS (HR: 0.61, 95% CI: 0.54-0.68) compared to control treatments. Subgroup analyses revealed consistent benefits across both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) populations, with no significant differences between cancer types. Similarly, the efficacy of tislelizumab was comparable whether administered as monotherapy or in combination with chemotherapy. Low heterogeneity was observed among the included studies, suggesting consistency in treatment effects. Follow-up duration across studies ranged from 14.2 to 16.7 months. These findings indicate that tislelizumab, either alone or combined with chemotherapy, is an effective treatment option for lung cancer patients, demonstrating significant improvements in survival outcomes. However, further high-quality RCTs are needed to validate these results, particularly in SCLC patients, where evidence is limited to a single study. Future research should also consider patient-specific factors such as age, gender, and comorbidities to refine treatment strategies.
- Open Access
- 24 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77909
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio on Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis
Transcatheter aortic valve implantation (TAVI) has emerged as a revolutionary treatment for severe aortic stenosis, but predicting post-procedure outcomes remains challenging. This systematic review and meta-analysis investigated the association between neutrophil-to-lymphocyte ratio (NLR) and mortality in TAVI patients. We searched major databases from January 2010 to November 2024, including studies examining pre-procedural NLR and mortality outcomes in TAVI patients. Eight retrospective studies comprising 9,948 participants were included. The follow-up duration ranged from three to 36 months. Meta-analysis using a random-effects model revealed that elevated NLR was significantly associated with increased mortality risk (RR: 1.37, 95% CI: 1.08-1.74). Substantial heterogeneity was observed (I-square: 77.3%). Meta-regression analysis identified follow-up duration as a significant predictor explaining 62.5% of the heterogeneity, while other variables including age, gender, diabetes, and hypertension showed minimal impact. Sensitivity analyses demonstrated the robustness of findings, with no individual study significantly influencing the overall effect size. The association between elevated NLR and increased mortality risk may be explained by neutrophils' role in inflammatory responses and tissue damage, coupled with reduced lymphocyte-mediated immune regulation. Despite limitations including NLR cut-off variations and heterogeneity in study designs, our findings suggest that NLR serves as a valuable prognostic marker for mortality risk in TAVI patients. Future research should focus on standardizing NLR thresholds and exploring subgroup-specific effects to enhance its clinical utility.
- 24 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77909
Open AccessThe Prognostic Value of Neutrophil-to-Lymphocyte Ratio on Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis
Transcatheter aortic valve implantation (TAVI) has emerged as a revolutionary treatment for severe aortic stenosis, but predicting post-procedure outcomes remains challenging. This systematic review and meta-analysis investigated the association between neutrophil-to-lymphocyte ratio (NLR) and mortality in TAVI patients. We searched major databases from January 2010 to November 2024, including studies examining pre-procedural NLR and mortality outcomes in TAVI patients. Eight retrospective studies comprising 9,948 participants were included. The follow-up duration ranged from three to 36 months. Meta-analysis using a random-effects model revealed that elevated NLR was significantly associated with increased mortality risk (RR: 1.37, 95% CI: 1.08-1.74). Substantial heterogeneity was observed (I-square: 77.3%). Meta-regression analysis identified follow-up duration as a significant predictor explaining 62.5% of the heterogeneity, while other variables including age, gender, diabetes, and hypertension showed minimal impact. Sensitivity analyses demonstrated the robustness of findings, with no individual study significantly influencing the overall effect size. The association between elevated NLR and increased mortality risk may be explained by neutrophils' role in inflammatory responses and tissue damage, coupled with reduced lymphocyte-mediated immune regulation. Despite limitations including NLR cut-off variations and heterogeneity in study designs, our findings suggest that NLR serves as a valuable prognostic marker for mortality risk in TAVI patients. Future research should focus on standardizing NLR thresholds and exploring subgroup-specific effects to enhance its clinical utility.
- Open Access
- 25 October 2024
- Published by Springer Nature in Cureus
- Vol. 16 (10) , e72351
Comparison of Apixaban, Rivaroxaban, Dabigatran, and Vitamin K Antagonists in Patients With Atrial Fibrillation and Liver Disease: A Network Meta-Analysis
Atrial fibrillation (AF) patients with liver disease present unique challenges in anticoagulation management due to increased risks of both thromboembolism and bleeding. This network meta-analysis aimed to compare the efficacy and safety of direct oral anticoagulants (DOACs), apixaban, rivaroxaban, and dabigatran, with vitamin K antagonists (VKAs) in this specific patient population. We conducted a comprehensive literature search across multiple databases, identifying seven studies (six observational and one randomized controlled trial) that met our inclusion criteria. The primary outcomes were the risk of stroke or systemic embolism (SE) and bleeding events. Our analysis revealed that all three DOACs demonstrated superior efficacy and safety profiles compared to VKAs. Apixaban showed the most favorable outcomes, with the highest probability of being the most effective in preventing both stroke/SE (RR: 0.51, 95% CI: 0.38-0.67) and bleeding events (RR: 0.54, 95% CI: 0.43-0.69). Rivaroxaban and dabigatran also significantly reduced the risk of these outcomes compared to VKAs but to a lesser extent than apixaban. Notably, rivaroxaban was associated with a slightly increased bleeding risk compared to apixaban (RR: 0.76, 95% CI: 0.58-0.99). The consistency of our network model was confirmed through both global and local tests. While these findings provide valuable guidance for clinicians, the study's limitations, including the predominance of observational data, highlight the need for large-scale randomized controlled trials. Future research should focus on clearly defined anticoagulant dosing regimens and comprehensive assessments of cirrhosis status to further optimize anticoagulation strategies in AF patients with liver disease.
- 25 October 2024
- Published by Springer Nature in Cureus
- Vol. 16 (10) , e72351
Open AccessComparison of Apixaban, Rivaroxaban, Dabigatran, and Vitamin K Antagonists in Patients With Atrial Fibrillation and Liver Disease: A Network Meta-Analysis
Atrial fibrillation (AF) patients with liver disease present unique challenges in anticoagulation management due to increased risks of both thromboembolism and bleeding. This network meta-analysis aimed to compare the efficacy and safety of direct oral anticoagulants (DOACs), apixaban, rivaroxaban, and dabigatran, with vitamin K antagonists (VKAs) in this specific patient population. We conducted a comprehensive literature search across multiple databases, identifying seven studies (six observational and one randomized controlled trial) that met our inclusion criteria. The primary outcomes were the risk of stroke or systemic embolism (SE) and bleeding events. Our analysis revealed that all three DOACs demonstrated superior efficacy and safety profiles compared to VKAs. Apixaban showed the most favorable outcomes, with the highest probability of being the most effective in preventing both stroke/SE (RR: 0.51, 95% CI: 0.38-0.67) and bleeding events (RR: 0.54, 95% CI: 0.43-0.69). Rivaroxaban and dabigatran also significantly reduced the risk of these outcomes compared to VKAs but to a lesser extent than apixaban. Notably, rivaroxaban was associated with a slightly increased bleeding risk compared to apixaban (RR: 0.76, 95% CI: 0.58-0.99). The consistency of our network model was confirmed through both global and local tests. While these findings provide valuable guidance for clinicians, the study's limitations, including the predominance of observational data, highlight the need for large-scale randomized controlled trials. Future research should focus on clearly defined anticoagulant dosing regimens and comprehensive assessments of cirrhosis status to further optimize anticoagulation strategies in AF patients with liver disease.
- Open Access
- 4 September 2024
- Published by Springer Nature in Cureus
- Vol. 16 (9) , e68602
Comparison of Efficacy of Atorvastatin and Rosuvastatin in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality worldwide. Statins, particularly atorvastatin, and rosuvastatin, are crucial in managing cholesterol levels and reducing cardiovascular risk in ACS patients. However, direct comparative studies between these two statins are limited. This meta-analysis aimed to compare the efficacy of atorvastatin and rosuvastatin in reducing major adverse cardiovascular events (MACE) and all-cause mortality in patients with ACS. A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Scopus for studies published up to July 2024. Randomized controlled trials and observational studies directly comparing atorvastatin and rosuvastatin in ACS patients were included. The primary outcomes were the incidence of MACE and all-cause mortality. Six studies involving 4195 patients were included in the meta-analysis. Pooled analysis showed no statistically significant difference between atorvastatin and rosuvastatin in reducing MACE [risk ratio (RR): 0.91, 95% confidence interval (CI): 0.68 to 1.22, p-value: 0.54] or all-cause mortality (RR: 0.94, 95% CI: 0.52 to 1.70, p-value: 0.83). No significant heterogeneity was observed among the studies (I-square: 0% for both outcomes). This meta-analysis suggests that atorvastatin and rosuvastatin have comparable efficacy in reducing MACE and all-cause mortality in ACS patients. These findings provide clinicians with flexibility in choosing between these statins based on individual patient factors. However, further large-scale randomized controlled trials are needed to confirm these results and explore potential differences in specific patient subgroups.
- 4 September 2024
- Published by Springer Nature in Cureus
- Vol. 16 (9) , e68602
Open AccessComparison of Efficacy of Atorvastatin and Rosuvastatin in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality worldwide. Statins, particularly atorvastatin, and rosuvastatin, are crucial in managing cholesterol levels and reducing cardiovascular risk in ACS patients. However, direct comparative studies between these two statins are limited. This meta-analysis aimed to compare the efficacy of atorvastatin and rosuvastatin in reducing major adverse cardiovascular events (MACE) and all-cause mortality in patients with ACS. A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Scopus for studies published up to July 2024. Randomized controlled trials and observational studies directly comparing atorvastatin and rosuvastatin in ACS patients were included. The primary outcomes were the incidence of MACE and all-cause mortality. Six studies involving 4195 patients were included in the meta-analysis. Pooled analysis showed no statistically significant difference between atorvastatin and rosuvastatin in reducing MACE [risk ratio (RR): 0.91, 95% confidence interval (CI): 0.68 to 1.22, p-value: 0.54] or all-cause mortality (RR: 0.94, 95% CI: 0.52 to 1.70, p-value: 0.83). No significant heterogeneity was observed among the studies (I-square: 0% for both outcomes). This meta-analysis suggests that atorvastatin and rosuvastatin have comparable efficacy in reducing MACE and all-cause mortality in ACS patients. These findings provide clinicians with flexibility in choosing between these statins based on individual patient factors. However, further large-scale randomized controlled trials are needed to confirm these results and explore potential differences in specific patient subgroups.
- Open Access
- 11 July 2024
- Published by Springer Nature in Cureus
- Vol. 16 (7) , e64311
Comparison of the Clinical Manifestations of Acute Coronary Syndrome Between Diabetic and Non-diabetic Patients: A Systematic Review and Meta-Analysis
The presentation of acute coronary syndrome (ACS) in patients with type 2 diabetes mellitus (T2DM) may differ from that of non-diabetic patients, potentially leading to delayed diagnosis and treatment. This metaanalysis aimed to compare the clinical presentation of ACS between diabetic and non-diabetic patients. A systematic search of PubMed, Excerpta Medica database (EMBASE), and Web of Science databases was conducted for observational studies published from January 2010 onwards. Studies comparing ACS symptoms between diabetic and non-diabetic patients were included. The odds ratio (OR) with 95% confidence intervals (CI) was calculated using a random-effects model. Eight studies with a total of 29,503 patients (23.03% diabetic) were included. Diabetic patients were significantly less likely to present with chest pain compared to non-diabetic patients (OR: 0.43, 95% CI: 0.30 to 0.63, p<0.001). Anxiety (OR: 2.20, 95% CI: 1.17-4.14), shortness of breath (OR: 1.49, 95% CI: 1.11-2.01), and neck pain (OR: 1.62, 95% CI: 1.032.54) were significantly more common in diabetic patients. Sweating/cold sweat was less common in diabetics (OR: 0.60, 95% CI: 0.34-1.07), though not statistically significant. Other symptoms showed minimal differences between groups. High heterogeneity was observed across studies for most symptoms. This meta-analysis demonstrates that diabetic patients with ACS are less likely to experience typical chest pain and more likely to present with atypical symptoms such as anxiety, shortness of breath, and neck pain. These findings emphasize the need for healthcare providers to maintain high vigilance for atypical ACS presentations in diabetic patients. Tailored diagnostic approaches, modified triage protocols, and enhanced patient education are crucial to improving the timely diagnosis and treatment of ACS in this high-risk population.
- 11 July 2024
- Published by Springer Nature in Cureus
- Vol. 16 (7) , e64311
Open AccessComparison of the Clinical Manifestations of Acute Coronary Syndrome Between Diabetic and Non-diabetic Patients: A Systematic Review and Meta-Analysis
The presentation of acute coronary syndrome (ACS) in patients with type 2 diabetes mellitus (T2DM) may differ from that of non-diabetic patients, potentially leading to delayed diagnosis and treatment. This metaanalysis aimed to compare the clinical presentation of ACS between diabetic and non-diabetic patients. A systematic search of PubMed, Excerpta Medica database (EMBASE), and Web of Science databases was conducted for observational studies published from January 2010 onwards. Studies comparing ACS symptoms between diabetic and non-diabetic patients were included. The odds ratio (OR) with 95% confidence intervals (CI) was calculated using a random-effects model. Eight studies with a total of 29,503 patients (23.03% diabetic) were included. Diabetic patients were significantly less likely to present with chest pain compared to non-diabetic patients (OR: 0.43, 95% CI: 0.30 to 0.63, p<0.001). Anxiety (OR: 2.20, 95% CI: 1.17-4.14), shortness of breath (OR: 1.49, 95% CI: 1.11-2.01), and neck pain (OR: 1.62, 95% CI: 1.032.54) were significantly more common in diabetic patients. Sweating/cold sweat was less common in diabetics (OR: 0.60, 95% CI: 0.34-1.07), though not statistically significant. Other symptoms showed minimal differences between groups. High heterogeneity was observed across studies for most symptoms. This meta-analysis demonstrates that diabetic patients with ACS are less likely to experience typical chest pain and more likely to present with atypical symptoms such as anxiety, shortness of breath, and neck pain. These findings emphasize the need for healthcare providers to maintain high vigilance for atypical ACS presentations in diabetic patients. Tailored diagnostic approaches, modified triage protocols, and enhanced patient education are crucial to improving the timely diagnosis and treatment of ACS in this high-risk population.
- Open Access
- 25 May 2024
- Published by Springer Nature in Cureus
- Vol. 16 (5) , e61069
Impact of Elevated Lipoprotein A on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
Lipoprotein(a) (Lp(a)) is an inherited lipoprotein particle associated with increased risk of atherosclerotic cardiovascular (CV) diseases. However, its impact on outcomes after percutaneous coronary intervention (PCI) remains unclear. The objective of this study was to assess the relationship between elevated Lp(a) levels and major adverse cardiovascular events (MACEs) and other outcomes in patients undergoing PCI. We systematically searched Embase, MEDLINE/PubMed, and Web of Science for studies published from 2015 to 2024 comparing CV outcomes between patients with elevated versus non-elevated Lp(a) levels after PCI. Primary outcome was MACE. Secondary outcomes included all-cause mortality, CV mortality, stroke, myocardial infarction, and revascularization. Risk ratios (RRs) were pooled using a random-effect model. Fifteen studies with 45,059 patients were included. Patients with elevated Lp(a) had a significantly higher risk of MACE (RR 1.38, 95% confidence interval (CI) 1.23-1.56). Elevated Lp(a) was also associated with increased risks of all-cause death (RR 1.26), CV death (RR 1.58), myocardial infarction (RR 1.44), revascularization (RR 1.38), and stroke (RR 1.18). Heterogeneity was considerable for some outcomes. This meta-analysis demonstrates that elevated Lp(a) levels are associated with worse CV outcomes, including higher rates of MACE, mortality, and recurrent ischemic events in patients undergoing PCI. Novel therapeutic approaches specifically targeting Lp(a) reduction may help mitigate residual CV risk in this high-risk population.
- 25 May 2024
- Published by Springer Nature in Cureus
- Vol. 16 (5) , e61069
Open AccessImpact of Elevated Lipoprotein A on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
Lipoprotein(a) (Lp(a)) is an inherited lipoprotein particle associated with increased risk of atherosclerotic cardiovascular (CV) diseases. However, its impact on outcomes after percutaneous coronary intervention (PCI) remains unclear. The objective of this study was to assess the relationship between elevated Lp(a) levels and major adverse cardiovascular events (MACEs) and other outcomes in patients undergoing PCI. We systematically searched Embase, MEDLINE/PubMed, and Web of Science for studies published from 2015 to 2024 comparing CV outcomes between patients with elevated versus non-elevated Lp(a) levels after PCI. Primary outcome was MACE. Secondary outcomes included all-cause mortality, CV mortality, stroke, myocardial infarction, and revascularization. Risk ratios (RRs) were pooled using a random-effect model. Fifteen studies with 45,059 patients were included. Patients with elevated Lp(a) had a significantly higher risk of MACE (RR 1.38, 95% confidence interval (CI) 1.23-1.56). Elevated Lp(a) was also associated with increased risks of all-cause death (RR 1.26), CV death (RR 1.58), myocardial infarction (RR 1.44), revascularization (RR 1.38), and stroke (RR 1.18). Heterogeneity was considerable for some outcomes. This meta-analysis demonstrates that elevated Lp(a) levels are associated with worse CV outcomes, including higher rates of MACE, mortality, and recurrent ischemic events in patients undergoing PCI. Novel therapeutic approaches specifically targeting Lp(a) reduction may help mitigate residual CV risk in this high-risk population.